The trial will include Norwegian adult males and females with symptomatic erosive inflammatory hand osteoarthritis.~Participants will be randomized 1:1 to either:~Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks (intervention group). Dosage can be reduced to as low as 10 mg if higher doses are not tolerated.~Placebo (control group).~Both arms will receive folic acid 1mg daily.~The treatment duration for both groups is 52 weeks.
A placebo-controlled randomized controlled trial exploring the effect of methotrexate on pain, function and structural outcomes in erosive inflammatory hand osteoarthritis.